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Restenosis is a substantial problem after arterial
reconstructive therapy with angioplasty and bypass
grafting despite extensive advances of technology.
Coronary angioplasty has resulted in a restenosis rate
as high as 57% at 6 months.1,2 Vascular smooth mus-
cle cell (SMC) migration and proliferation are central
to the pathology of injury-induced intimal hyperpla-
sia and restenosis.3,4 Researchers have been investi-
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Purpose: Restenosis after angioplasty or bypass grafting to restore circulation to ischemic
organs is still an unsolved problem. Thrombin generated in high concentrations at the
sites of vascular injury plays a central role in thrombosis and hemostasis. α-Thrombin
has also been implicated as a mitogen for smooth muscle cell (SMC) proliferation that
contributes to arterial restenosis. Thrombomodulin has a high affinity of binding with
thrombin and converts thrombin from a procoagulant to an anticoagulant. This study
was designed to examine whether thrombomodulin could also moderate the thrombin-
mediated SMC proliferative response.
Methods: Porcine carotid artery SMCs (passages 4-7) were plated onto 96-well plates and
incubated for 3 days. After growth arrest in a defined serum-free medium for 2 to 3 days,
SMCs were subjected to the reagents as follows: (1) human α-thrombin, (2) recombinant
human soluble thrombomodulin containing a chondroitin sulfate moiety, (3) thrombin
receptor agonist peptide (SFLLRNPNDKYEPF), and (4) α-thrombin or thrombin recep-
tor agonist peptide combined with recombinant thrombomodulin (rTM). The viability
and proliferation status of SMCs were quantified with MTT (thiazolyl blue) mitochon-
drial function and bromodeoxyuridine (BrdU)–DNA incorporation assays. 
Results: Human α-thrombin increased SMC proliferation in a dose dependent manner
by more than 25% and 30% with thrombin 1 U/mL to 3 U/mL compared with control
groups on day 7 (P < .006). rTM concentrations from 0.5 µg/mL to 3 µg/mL have no
significant effect on SMC growth. The stimulation of SMC proliferation induced by α-
thrombin at 0.5 U/mL, 1 U/mL, and 2 U/mL was significantly inhibited with rTM at
2 µg/mL and 3 µg/mL on days 3, 7, and 10 as evaluated with MTT assay (P < .01 to
< .05) and BrdU-DNA incorporation assay on day 3 (P < .008). Thrombin receptor
agonist peptide increased SMC BrdU-DNA incorporation at 48 hours (P < .007), and
its effect was not altered by rTM. 
Conclusion: rTM containing all of the extracellular domains of thrombomodulin inhibits
the effect of thrombin on SMC proliferation in vitro. Because thrombin is a mitogenic
mediator of SMC in vascular injury, inhibition of its function in vivo could help to pre-
vent SMC hyperplasia. The success of further studies in vivo may lead to use of rTM for
decreasing or preventing arterial restenosis. (J Vasc Surg 2000;32:804-13.)
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gating the mechanism of SMC growth and methods
of preventing or decreasing neointimal hyperplasia.4-
12 Although heparin is a potent inhibitor of SMC
growth and intimal hyperplasia in some animal mod-
els, it has not been effective in inhibiting restenosis in
both humans and a baboon model.10 Gene transfer
techniques have also been used for understanding and
inhibiting intimal hyperplasia.12-15 SMCs transduced
with replicated-defective retrovirus encoding tissue
inhibitor of matrix metalloproteinase–1 were seeded
onto the surface of balloon-injured rat carotid arter-
ies.14 It was shown that tissue inhibitor of matrix met-
alloproteinase–1 suppressed the proteolytic activity of
matrix metalloproteinase and the migration of the
SMCs, therefore suppressing intimal thickening. Basic
fibroblast growth factor (bFGF), which is located
inside the SMC of the artery and released from
injured and dying cells, stimulates the first wave of
SMC growth and is considered to be a major factor in
the intimal hyperplastic response.11 At 14 days in a
balloon-injured rabbit femoral artery, a marked inhi-
bition of neointimal thickening was found in the ade-
novirus encoding rat antisense bFGF–transfected
arteries.12 However, the study demonstrated that the
effect of antisense bFGF gene delivery on the limita-
tion of intimal thickening after balloon injury is not
mediated by an inhibition of cellular proliferation, but
rather by induction of apoptosis and cellular demise.
Therefore, the identity of the factor(s) responsible for
neointimal SMC proliferation is still not fully clear. 
Invasive treatment of symptomatic arterial
stenoses unavoidably causes vessel injury and induces
thrombin generation in high concentrations at the
treated site.4-7 Thrombin, by virtue of its involve-
ment in thrombosis and hemostasis, also plays an
important role in the process of intimal hyperpla-
sia.4,8 α-Thrombin has been shown as a potent mito-
gen for cultured rat5 and bovine aortic SMCs6 as well
as in injured arteries of nonhuman primates.9
Thrombomodulin, an endothelial cell mem-
brane glycoprotein, forms a high-affinity complex
with thrombin and converts thrombin from a pro-
coagulant to an anticoagulant enzyme.16,17 The
thrombomodulin-thrombin complex inhibits the
coagulant property of thrombin and potently acti-
vates anticoagulant protease protein C, therefore
inhibiting thrombus formation.16-19 The structure
of thrombomodulin has been well characterized
and consists of an amino-terminal domain that is
homologous to the family of C-type lectins, six tan-
dem repeated epidermal growth factor–like
domains, a Ser/Thr–rich domain containing at
least five O-linked oligosaccharides, a transmem-
brane domain, and a short cytoplasmic tail.17-25
Recombinant human thrombomodulin, a soluble
derivative of human thrombomodulin by deletion
of the transmembrane and cytoplasmic tail
domains, has shown potent anticoagulant activity
in vitro and antithrombotic activity in animal mod-
els.26-28 Recombinant human thrombomodulin has
also been shown to block thrombin-mediated
cleavage of thrombin receptor on human umbilical
vein endothelial cells through competition at
thrombin’s anion-binding site 1.29 Grinnell and
Berg30 demonstrated that the coexpression of
thrombomodulin with thrombin receptor on clonal
thrombin receptor–positive/thrombomodulin-
negative rabbit intimal SMCs resulted in a modula-
Fig 1. Effect of α-thrombin on SMC proliferation. SMC proliferation was quantified with MTT mito-
chontrial function assay on day 7. Results represent the percent growth as compared with buffer con-
trol (vehicle PBS) groups. Values are means ± SEM of four individual experiments. Each experimental
group was run in quadruplicate. Asterisk represents significance from control groups, P < .006. 
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tion of cellular response to thrombin, and suggest-
ed that it might control thrombin-induced prolif-
erative events. The purpose of the current study
was to determine whether thrombomodulin could
also inhibit the proliferative effect of thrombin on
porcine carotid arterial SMCs in vitro. 
MATERIALS AND METHODS
Cell preparation
SMCs were explanted from piglet carotid arter-
ies and characterized by their elongated morpholo-
gy and stained positive for monoclonal anti–α-SMC
actin antibody as determined by indirect immuno-
fluorescence. 
For the preparation of proliferation experiments,
SMCs (passages 4-7) were seeded onto 96-well plates
at a density of 6 to 7 × 103 per well in the culture medi-
um (Dulbecco modified Eagle medium [DMEM]),
which contained high glucose supplemented with 15%
fetal bovine serum (Life Technologies; GibcoBRL,
Grand Island, NY), 50 U/mL of penicillin; and 50
µg/mL of streptomycin at 37°C in a 5% carbon diox-
ide/95% air incubator for 3 days. The cells were then
washed twice with DMEM that contained no fetal
bovine serum and growth arrested for 3 days in a
defined serum-free medium (DMEM/Ham’s F12
[1:1], GibcoBRL), which contained insulin at 10–6
mol/L (5.8 µg/mL) (Sigma Chemical Co, St Louis,
Mo), transferrin at 5 µg/mL (Sigma), ovalbumin at 1
mg/mL (Sigma), penicillin at 100 U/mL, and strep-
tomycin at 100 µg/mL). All the reagents were filtered
through a 0.45-µm filter (Millex-HV; Millipore,
Bedford, Mass) before experiments.
Protocols of experiments
The experimental groups, along with their appro-
priate buffer control (phosphate-buffered saline [PBS]
with and without Tris-HCl) groups, were arranged in
the same column of a 96-well culture plate. Each
group was in quadruplicate. The culture media were
changed every 2 to 3 days. The viability and prolifera-
tion status of SMCs were quantified with thiazolyl
blue (MTT) cell mitochondrial function assay and
bromodeoxyuridine (BrdU)–DNA incorporation
assay on the defined days. After the cells were growth
arrested for 3 days, proliferation experiments were
started by replacing the culture medium with the fresh
defined serum-free medium with the use of media
supplemented with reagents described below.
Evaluation of the effect of α-thrombin on
SMC proliferation. The growth-arrested SMCs
were cultured in the defined serum-free medium sup-
plemented with human α-thrombin with the concen-
trations ranging from 0.1 U/mL (0.7 nmol/L) to 3
U/mL (Calbiochem, San Diego, Calif). In control
groups, the growth-arrested SMCs were cultured in
the defined serum-free medium supplemented with
vehicle PBS (Dulbecco’s Ca2+ and Mg2+ free,
GibcoBRL, Life Technologies). The SMC prolifera-
tion status was evaluated with MTT assay on day 7.
Evaluation of the effect of recombinant
thrombomodulin (rTM) on SMC proliferation.
The growth-arrested SMCs were cultured in the
defined serum-free medium supplemented with
recombinant human soluble thrombomodulin
TMD1 (CS+) (rTM; Eli Lilly and Co, Indianapolis,
Ind) ranging from 0.5 µg/mL (10 nmol/L) to 3
µg/mL, or with vehicle Tris-HCl buffer (20
mmol/L Tris-HCl, 0.1 mol/L sodium chloride, pH
7.4) (control groups). The SMC proliferation status
was evaluated with MTT assay on day 7.
Evaluation of the effect of hirudin and rTM
with and without α-thrombin on SMC prolifer-
ation. The growth-arrested SMCs were cultured in
the defined serum-free medium supplemented with
(1) α-thrombin at 2 U/mL (14 nmol/L), (2)
hirudin (Sigma) at 30 nmol/L with and without α-
thrombin at 2 U/mL, and (3) rTM at 2 µg/mL (40
nmol/L) with and without α-thrombin at 2 U/mL,
or with vehicle PBS, with and without Tris-HCl
buffer (control groups). The SMC proliferation sta-
tus was evaluated with MTT assay on day 7.
Evaluation of the effect of rTM on SMC pro-
liferation induced by α-thrombin. The growth-
arrested SMCs were cultured in the defined serum-
Table I. Effect of rTM on SMC growth
rTM 0.5 µg/mL rTM 1 µg/mL rTM 1.5 µg/mL rTM 2 µg/mL rTM 3 µg/mL
rTM (OD) 0.11 ± 0.01 0.12 ± 0.01 0.13 ± 0.01 0.13 ± 0.01
Control (OD) 0.11 ± 0.01 0.13 ± 0.01 0.13 ± 0.01 0.15 ± 0.01
Percent of control 96 ± 3 91 ± 3 98 ± 4 96 ± 3 102 ± 5
Effect of recombinant human thrombomodulin TMD1 (CS+) on SMC growth was evaluated on day 7 with MTT mitochondrial func-
tion assay. Each point represents mean ± SEM of four individual experiments. Each experimental group was run in quadruplicate. There
was no statistical significance between rTM groups and control groups. 
OD, Optical density.
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free medium supplemented with α-thrombin at 0.5
U/mL, 1 U/mL, and 2 U/mL, with and without
rTM at 1 µg/mL, 2 µg/mL, and 3 µg/mL, respec-
tively. The SMC proliferation status was evaluated
with MTT mitochondrial function assay on days 3, 7
and 10. BrdU-DNA incorporation of SMCs was
evaluated with SMCs cultured with α-thrombin at 1
U/mL with and without rTM at 1 µg/mL, 2
µg/mL, and 3 µg/mL on day 3.
Evaluation of the effect of thrombin receptor
agonist peptide (SFLLRNPNDKYEPF, SFLL) on
SMC proliferation. After they were growth arrested
for 2 days, SMCs were subjected to SFLL
(Calbiochem) with concentrations ranging from 5
µmol/L to 40 µmol/L, or SFLL at 20 µmol/L with
and without rTM at 100 nmol/L. SMCs were incu-
bated with BrdU-labeling solution for 18 hours.
BrdU-DNA incorporation of SMCs was evaluated at
48 hours. For MTT mitochondrial function assay,
SMCs were growth arrested for 3 days, then subjected
to SFLL at 20 µmol/L with and without rTM at 100
nmol/L. The MTT assay was performed at 48 hours.
Assay methods
MTT mitochondrial function assay. MTT
(Sigma) is a water soluble tetrazolium salt. Insoluble
purple formazan crystals form if the cell mitochon-
dria are functioning and the cells are viable. On the
day of assay, the culture media were replaced with
DMEM without phenol red. SMCs were incubated
with MTT (0.5 mg/mL) for 5 hours at 37°C in a 5%
carbon dioxide/95% air incubator. The formed pur-
ple formazan crystals were solubilized with solvent
solution (50% N,N-dimethylformamide, 10 g of
sodium dodecyl sulfate, 2.5 mL of 80% glacial acetic
acid [Sigma], and 2.5 mL of 1 N of HCl in 100 mL
deionized distilled water) and mixed thoroughly
with a pipette. Optical density of converted dye was
measured at a wavelength of 492 nm with a spec-
trophotometer (SLT Spectra, TECAN US INC,
Research Triangle Park, NC).
MTT assay is a reliable alternative to the tritiated
thymidine uptake for measurement of cell prolifera-
tion.31,32 It was reported that the MTT formazan
generated was directly proportional to the number
of lymphoma cells.31 We tested the correlation
between the number of SMCs from 3000 to 9500
and the amount of MTT formazan generated. The
results also showed a linear relationship between
optical density and cell count (data not shown).
BrdU-DNA incorporation assay. BrdU, a thymi-
dine analog, is taken up by proliferating cells into cel-
lular DNA. This process is analogous to the long-
established tritiated thymidine uptake technique.
Colorimetric immunoassay for the quantification of
cell proliferation, based on the measurement of BrdU
incorporation during DNA synthesis, is a nonradioac-
tive alternative to the tritiated thymidine incorporation
assay.33 A Cell Proliferation ELISA, BrdU (colorimet-
ric) Kit (Roche Molecular Biochemicals, Indianapolis,
Ind) was used. On the second day of incubation with
the experimental reagents, SMCs were labeled with
Fig 2. Effect of thrombin, hirudin, recombinant human soluble thrombomodulin (TMD1, CS+)
(rTM) on SMC proliferation. SMC proliferation was quantified with MTT mitochondrial function
assay on day 7. Results represent the percent growth as compared with buffer control (vehicle PBS ±
Tris buffer) groups. Values are means ± SEM of three individual experiments. Each experimental group
was run in quadruplicate. * represents significance from control groups, P < .006. ** represents sig-
nificance from thrombin alone group, P < .0005. 
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BrdU at 10 µmol/L for 18 hours at 37°C in a 5% car-
bon dioxide/95% air incubator. Then, SMCs were
fixed and denatured with the FixDenat reagent (this
reagent is included in the kit) for 30 minutes at room
temperature (RT), followed by incubation with
anti–BrdU-peroxidase antibody (0.2 U/mL) for 2
hours at RT. The cells were then washed with PBS
three times, and incubated with tetramethylbenzidine
(BM blue) for 30 minutes at RT. The substrate reac-
tion was stopped with 1 mol/L of H2SO4. After it was
shaken at 300 rpm for 1 minute, the optical density of
96-well plates was measured with a spectrophotome-
ter (MRX, DAYNEX Technologies, Inc, Chantilly, Va)
at a wavelength of 450 nm and a reference wavelength
of 750 nm. 
Statistical analysis 
Results are expressed as the mean ± SEM of three
or four individual experiments. Each experiment was
run in quadruplicate. Differences in SMC MTT for-
mazan formation and BrdU-DNA incorporation
between experimental groups and their appropriate
buffer control groups were compared by the use of a
nonparametric Wilcoxon matched pairs test. Differ-
ences in SMC MTT formazan formation and BrdU-
DNA incorporation between rTM combined with
thrombin groups and thrombin group alone were
compared by the use of a nonparametric Mann-
Whitney two-sample test. Differences were considered
significant at the 95% confidence level (P < .05).
RESULTS
α-Thrombin stimulated SMC proliferation.
The effect of α-thrombin on SMC proliferation as
evaluated with MTT mitochondrial function assay is
shown in Fig 1. α-Thrombin significantly increased
SMC proliferation in a dose dependent manner start-
ing at 0.25 U/mL. Compared with control (vehicle
PBS buffer) groups, SMC proliferation increased
20% to 35% with the stimulation of α-thrombin at
0.25 U/mL to 3 U/mL on day 7 (P < .006).
rTM has no effect on SMC growth. The
results of rTM alone on the effect of SMC growth
are shown in Table I. There was no significant effect
on SMC growth with the concentrations of rTM at
0.5 µg/mL to 3 µg/mL as compared with their
control (vehicle Tris-HCl buffer) groups on day 7.
Hirudin and rTM inhibited SMC prolifera-
tion induced by α-thrombin. The effect of rTM
on SMC proliferation was also compared with the
effect of hirudin (a direct thrombin inhibitor) in an
additional set of experiments. The results showed
that the SMC proliferation induced by α-thrombin
at 2 U/mL (14 nmol/L) was significantly inhibited
by hirudin at 30 nmol/L and rTM at 2 µg/mL (40
nmol/L) (P < .0005; Fig 2).
Table II. Effect of rTM on SMC proliferation induced by α-thrombin 
rTM 1 µg/mL rTM 2 µg/mL rTM 3 µg/mL 
TH 0.5 U/mL + TH 0.5 U/mL + TH 0.5 U/mL + TH 0.5 U/mL
Day 3 119 ± 4 109 ± 2 102 ± 4* 106 ± 3*
Day 7 120 ± 7 117 ± 5 105 ± 9* 105 ± 7*
Day 10 124 ± 4 114 ± 7 100 ± 7* 95 ± 5*
TH 1 U/mL rTM 1 µg/mL rTM 2 µg/mL rTM 3 µg/mL
+ TH 1 U/mL + TH 1 U/mL + TH 1 U/mL
Day 3 128 ± 6 114 ± 4 107 ± 3* 108 ± 3*
Day 7 137 ± 8 124 ± 5 116 ± 5* 104 ± 5*
Day 10 138 ± 5 119 ± 9 120 ± 5* 105 ± 6*
TH 2 U/mL rTM 1 µg/mL rTM 2 µg/mL rTM 3 µg/mL 
+ TH 2 U/mL + TH 2 U/mL + TH 2 U/mL
Day 3 128 ± 2 120 ± 2 110 ± 4* 113 ± 3*
Day 7 135 ± 8 124 ± 5 123 ± 4* 115 ± 5*
Day 10 137 ± 6 124 ± 16 122 ± 10* 118 ± 10*
Effect of recombinant human thrombomodulin at 1 µg/mL, 2 µg/mL and 3 µg/mL on SMC proliferation induced by human α-
thrombin at 0.5 U/mL, at 1 U/mL, and at 2 U/mL. Results were evaluated with MTT mitochondrial function assay on days 3, 7, and
10, respectively. Data represent mean ± SEM of percentage of their appropriate buffer control (PBS ± Tris-HCl) groups of three indi-
vidual experiments. Each experimental group was run in quadruplicate.
*Significance from thrombin alone group values, P < .01 to < .05.
T, α-Thrombin..
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rTM inhibited the effect of α-thrombin on
SMC DNA synthesis and proliferation. The effect
of rTM at 1 µg/mL, 2 µg/mL, and 3 µg/mL on
SMC DNA synthesis induced by α-thrombin at 1
U/mL was evaluated with BrdU-DNA incorpora-
tion assay on day 2 (Fig 3). The results demonstrat-
ed that DNA synthesis stimulated by thrombin at 1
U/mL was suppressed with rTM at 1 µg/mL and
was significantly inhibited with 2 µg/mL and 3
µg/mL as compared with their control (vehicle PBS
and/or Tris-HCl buffer) groups (P < .008). 
Experiments were also performed to study the
effect of three concentrations of rTM on SMC
growth in combination with three concentrations of
α-thrombin. SMCs were cultured in media with 1
µg/mL, 2 µg/mL, and 3 µg/mL of rTM combined
with α-thrombin at 0.5 U/mL, 1 U/mL, and 2
U/mL, respectively. SMC growth was evaluated on
days 3, 7, and 10 with MTT mitochondrial function
assay (Table II, Fig 4). SMC proliferation was signif-
icantly increased by α-thrombin with all three con-
centrations tested (P < .02). This effect of α-throm-
bin on SMC proliferation was suppressed by the
addition of rTM at 1 µg/mL and significantly inhib-
ited by rTM at 2 µg/mL and 3 µg/mL as compared
with their vehicle control groups (P < .003 to < .05).
Thrombin receptor agonist peptide SFLL sig-
nificantly stimulated SMC proliferation and its
effect was not affected with rTM. The effect of
SFLL (5-40 µmol/L) on SMC DNA synthesis is
shown in Fig 5, A. On day 2, the SFLL peptide sig-
nificantly stimulated SMC DNA synthesis at all con-
centrations tested. SFLL peptide at 20 µmol/L
increased SMC DNA synthesis more than 30% com-
pared with buffer control groups (P < .007). Further
increase in peptide concentration (ie, to 40 µmol/L)
did not result in significantly further increase in DNA
synthesis. Cotreatment of SMC with SFLL and rTM
did not modulate the effect of SFLL on either DNA
synthesis (Fig 5, B) or proliferation as evaluated with
MTT mitochondrial function assay (Fig 5, C).
DISCUSSION
The cellular components of the vascular wall are
normally quiescent (in a growth-arrested state, 0.06%
turnover per day) and proliferate only in response to
injury.15 Vascular injury results in activation of the
coagulation cascade, which can generate approxi-
mately 140 nmol/L concentration of thrombin.7
Thrombin is the final product of the cascade and a
potent activator of platelets leading to aggregation
and thrombus formation. Activated platelets also
release a variety of cytokines, such as platelet-derived
growth factor, transforming growth factor–β, and
insulin-like growth factor–1, which can promote
SMC migration and proliferation, as well as matrix
deposition. Therefore, thrombin generation also plays
an important role in the initiation of intimal hyper-
plasia.4,8,9 This study demonstrated that α-thrombin
was a potent mitogen for porcine carotid artery SMCs
in culture. In a defined serum-free medium, 48-hour
stimulation of thrombin at 1 U/mL increased SMC
DNA synthesis more than 20% compared with PBS
control groups. α-Thrombin at 1 U/mL induced
SMC proliferation more than 35% on days 7 and 10
with SMC mitochondrial function assay, which was
similar to a previous report of approximately 35% tri-
tiated thymidine uptake increase of bovine aortic
Fig 3. Effect of recombinant human soluble thrombomodulin (TMD1, CS+) (rTM) on SMC prolif-
eration induced by α-thrombin. SMC DNA synthesis was evaluated with BrdU-DNA incorporation
assay on day 3. Results represent the percentage of buffer control (vehicle PBS with and without Tris-
HCl buffer) groups. Values are means ± SEM of three individual experiments. Each experimental
group was run in quadruplicate. * represents significance from control groups, P < .03. ** represents
significance from the thrombin group value, P < .008. 
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SMCs on day 7.6 If this effect occurred in vivo after
vascular angioplasty or surgical procedures, it would
lead to significant neointimal hyperplasia and resteno-
sis. Hemodynamically, this could be critical, especial-
ly for the small caliber arteries (ie, coronary and
peripheral arteries).
Thrombin inhibitors34-37 and antisense thrombin
receptor oligodeoxynucleotide38 have been studied
for the prevention of SMC proliferation. This study
demonstrated that hirudin, a direct thrombin
inhibitor, inhibited SMC proliferation induced by
thrombin. However, hirudin is rapidly cleared from
the mammalian circulation, exhibiting a catabolic half-
life of 1 hour or less in all laboratory animals tested.39
Recombinant hirudin and hirulog failed to improve
cardiac events after coronary angioplasty.35-37 The
antisense thrombin receptor oligodeoxynucleotide did
not inhibit intimal hyperplasia after vascular injury.38
This study showed that rTM significantly inhibited
SMC DNA synthesis and proliferative effect induced
by thrombin. Thrombomodulin is constitutively pro-
duced on the endothelium and functions as a key fac-
tor in maintaining the nonthrombogenic vessel surface.
rTM has demonstrated antithrombotic activity on
thrombin-induced thromboembolism in mice28 and
has prevented venous thrombosis in a rat model.26,27
The half-life of thrombomodulin is much longer than
hirudin in mammalian blood circulation, which has
been reported as 460 minutes for activated partial
thromboplastin time and 179 minutes for thrombin-
clotting time in rabbit circulation.40 Grinnell and
Berg30 transfected clonal thrombin-receptor–positive
and thrombomodulin-negative rabbit intimal SMCs
with an expression vector containing the cDNA for
full-length thrombomodulin. They demonstrated that
high levels of thrombomodulin on vascular SMCs
block thrombin-induced effects through the thrombin
receptor and that the signal, by means of the thrombin
receptor, is blocked by a compensating signal mediated
through thrombomodulin. We demonstrated directly
that the addition of either rTM at concentrations of 2
µg/mL and 3 µg/mL or hirudin at 30 nmol/L signif-
icantly inhibited the proliferative effect of α-thrombin
on arterial SMCs. This suggests that thrombomodulin
may be able to limit thrombin-induced proliferation
events after vessel injury.
The molecular mechanism of thrombin signaling
has been extensively reviewed by Coughlin.41
Thrombin binds and cleaves its seven transmembrane
domain receptors unmasking a new amino terminus,
which acts as a tethered ligand. This ligand binds to
the body of the thrombin receptor, activating the G-
protein linked cascade. The first five amino acids of the
receptor’s agonist peptide domain (SFLLR) are suffi-
cient to specify agonist activity. It has been reported
that α-thrombin stimulates rat aortic SMC prolifera-
tion through a proteolytically activated receptor.5 A
14-residue peptide (SFLLRNPNDSYEPF) corre-
sponding to amino acids 42 through 55 of the human
thrombin receptor had full efficacy in stimulating rat
Fig 4. Effect of recombinant human soluble thrombomodulin (TMD1, CS+) (rTM) on SMC prolif-
eration induced by α-thrombin. SMCs were cultured in media with thrombin at 1 U/mL alone (solid
bar), thrombin at 1 U/mL combined with rTM at 1 µg/mL (striped bar), at 2 µg/mL (checkered bar),
and at 3 µg/mL (open bar) of rTM. SMC proliferation was quantified with MTT mitochondrial func-
tion assay on days 3, 7, and 10, respectively. Results represent the percent growth as compared with
buffer control (vehicle PBS with and without Tris-HCl buffer) groups. Values are means ± SEM of
three individual experiments. Each experimental group was run in quadruplicate. * represents signifi-
cance from thrombin-alone groups, P < .003 to < .05. 
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SMC proliferation. Where the thrombin receptor’s
agonist peptide domain binds and how this binding
event causes a transmembrane signal that allows the
receptor to activate G-proteins have yet to be 
elucidated. Our data demonstrated that SFLL-
RNPNDSYEPF significantly stimulated porcine
carotid artery SMC DNA synthesis on day 2, suggest-
ing that these cells express functional thrombin recep-
tor on their surface. As expected, treatment of SMCs
with both SFLL and rTM did not modulate the SFLL
Fig 5. Effect of thrombin receptor agonist peptide SPLLRNPNDSYEPF (SFLL) on SMC proliferation.
SMCs were subjected to a serial concentration of SFLL (A). SMC DNA replication was evaluated with
BrdU-DNA incorporation assay at 48 hours. Results represent the percent growth as compared with buffer
control groups. Values are means ± SEM of three individual experiments. Each group was run in quadru-
plicate. Asterisk represents significance from control groups, P < .007 (A). Effect of rTM at 100 nmol/L on
the stimulation effect of SMC DNA synthesis (B) and SMC proliferation (C) induced by SFLL at 20
µmol/L. SMC DNA synthesis was evaluated with BrdU-DNA incorporation assay, and SMC proliferation
was evaluated with mitochondrial function assay at 48 hours. Results represent the percent growth as com-
pared with buffer control groups. Values are means ± SEM of three individual experiments. Each group was
run in quadruplicate. Asterisk represents significance from control groups, P < .003. There was no signifi-
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effect on SMC proliferation or DNA synthesis, sug-
gesting there is no direct interaction of rTM with the
thrombin receptor itself. 
The mechanism of rTM inhibiting human umbil-
ical vein endothelial cell proliferation induced by
thrombin was shown to be rTM blocking thrombin-
mediated cleavage of thrombin receptor by means of
competitive binding at thrombin’s anion binding site
1.29 In a previous study on the clonal rabbit intimal
SMCs,30 the degree to which thrombin receptor acti-
vation was blocked directly correlated with the level
of thrombomodulin expressed on the cell surface. 
Our results, which demonstrated no proliferative
response of SMCs to rTM treatment alone (up to 60
nmol/L), differ from those of Tohda et al,42 who
demonstrated mitogenic effect of rTME1-6 on rat tho-
racic aorta SMCs. A direct comparison between their
results and ours is complicated by a number of issues
relating to experimental conditions, specifically the
rTM molecules themselves and the source of SMCs.
The SMCs used by Tohda et al were derived from rat
aorta, whereas ours were from porcine carotid artery.
It has been reported that SMC proliferation was
species or anatomic-position related.43 Furthermore,
it should be emphasized that the rTM used in our
study consisted of the entire extracellular domain of
human thrombomodulin, which contained the natu-
rally occurring chondroitin sulfate modification to the
O-glycosylation domain. The rTM used by Tohda et
al was rTME1-6, which consisted of only the six epi-
dermal growth factor–like domains, whereas the
amino-terminal sequence and the Ser/Thr-rich region
were deleted.44 It has been shown that a chondroitin
sulfate moiety attached to the Ser/Thr-rich domain of
thrombomodulin increases its affinity for thrombin
approximately 10- to 20-fold, which makes thrombo-
modulin a more potent inhibitor of coagulation, alter-
ing thrombin’s conformation and specificity, as well as
accelerating its thrombin inhibition.17,24
The mechanism of rTM inhibiting the mitogenic
effect of thrombin on SMCs needs to be further
studied. However, observations that rTM was
unable to block SMC responses to the thrombin
receptor agonist SFLL suggest that rTM binding to
thrombin prevents activation of its tethered ligand
receptor, presumably by masking anion-binding
exosite 1 of thrombin.45,46
CONCLUSIONS
Human α-thrombin stimulates porcine carotid
arterial SMC proliferation in vitro as demonstrated
with SMC DNA synthesis and mitochondrial function
assays. This study first demonstrates that recombinant
human thrombomodulin, consisting of all the extracel-
lular domains and the naturally occurring chondroitin
sulfate moiety, is able to effectively inhibit thrombin-
induced SMC proliferation. Thrombin receptor ago-
nist SFLL increases SMC proliferation, and its direct
effect on SMCs is not blocked by rTM. By virtue of
thrombomodulin’s multiple unique activities for
inhibiting both procoagulant and mitogenic effects of
thrombin, rTM may prove a useful therapeutic agent in
decreasing or preventing arterial restenosis. 
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